Dado oficial do USPTO

DAWNRAYS

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: MistaEscritório: US

Ativar vigilância desta marca Falar com especialista

Snapshot rápido

ST13

US500000079085256

Classe

Pedido

79085256

Registro

3976651

Ver no USPTO

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

Atualização mais recente

07/04/2023

Classificação

Registrada

Tipo de marca

Mista

Classes Nice

Data de depósito

27/04/2010

Data de registro

14/06/2011

Data de expiração

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

31/12/2021

Última transação

07/04/2023

Escritório responsável

United States Patent and Trademark Office

Código da situação

709

Cadastro oficial

Principal Register

Código do desenho

Tipo de titular

Localização do titular

Examinador

JUN, WON KYUNG WENDY

Unidade examinadora

L30

Localização atual

GENERIC WEB UPDATE

Descrição da marca

The mark consists of the wording "DAWNRAYS". To the left of the wording is a design element of a circle superimposed over a shaded rectangle.

Titulares e representantes

Titulares

Suzhou Dawnrays Pharmaceutical Co., Ltd.

Representantes

SUZHOU DAWNRAYS PHARMACEUTICAL CO., LTD.

Classificação técnica

Classes Nice

Classe 5

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 5

Chemical preparations for pharmaceutical purposes for the treatment of the nervous system diseasesthe immune system diseasesthe cardio-vascular system diseasesthe metabolic system diseasesthe respiratory system diseasesthe digestive system diseasesthe circulatory system diseasesthe urinary system diseasesthe endocrine system diseasesthe blood system diseasesskin disordersgynecological diseasesophthalmic diseasesmental disordersinflammatory disordersliver diseasestumor and deficiency diseases; Pharmaceutical preparations for injection for the treatment of the nervous system diseasesthe immune system diseasesthe cardio-vascular system diseasesthe metabolic system diseasesthe respiratory system diseasesthe digestive system diseasesthe circulatory system diseasesthe urinary system diseasesthe endocrine system diseasesthe blood system diseasesskin disordersgynecological diseasesophthalmic diseasesmental disordersinflammatory disordersliver diseasestumor and deficiency diseases; Pharmaceutical preparations in tablet form for the treatment of the nervous system diseasesthe immune system diseasesthe cardio-vascular system diseasesthe metabolic system diseasesthe respiratory system diseasesthe digestive system diseasesthe circulatory system diseasesthe urinary system diseasesthe endocrine system diseasesthe blood system diseasesskin disordersgynecological diseasesophthalmic diseasesmental disordersinflammatory disordersliver diseasestumor and deficiency diseases; Raw material medicines for the treatment of the nervous system diseasesthe immune system diseasesthe cardio-vascular system diseasesthe metabolic system diseasesthe respiratory system diseasesthe digestive system diseasesthe circulatory system diseasesthe urinary system diseasesthe endocrine system diseasesthe blood system diseasesskin disordersgynecological diseasesophthalmic diseasesmental disordersinflammatory disordersliver diseasestumor and deficiency diseases; Chemico-pharmaceutical preparations for the treatment of the nervous system diseasesthe immune system diseasesthe cardio-vascular system diseasesthe metabolic system diseasesthe respiratory system diseasesthe digestive system diseasesthe circulatory system diseasesthe urinary system diseasesthe endocrine system diseasesthe blood system diseasesskin disordersgynecological diseasesophthalmic diseasesmental disordersinflammatory disordersliver diseasestumor and deficiency diseases; Chemical preparations for medical purposes for the treatment of the nervous system diseasesthe immune system diseasesthe cardio-vascular system diseasesthe metabolic system diseasesthe respiratory system diseasesthe digestive system diseasesthe circulatory system diseasesthe urinary system diseasesthe endocrine system diseasesthe blood system diseasesskin disordersgynecological diseasesophthalmic diseasesmental disordersinflammatory disordersliver diseasestumor and deficiency diseases; Prepared traditional Chinese medicines for the treatment of respiratory system diseasesdigestive system diseasesliver diseasescardio-vascular system diseases and nervous system diseases; Medicines for the treatment of the nervous system diseasesthe immune system diseasesthe cardio-vascular system diseasesthe metabolic system diseasesthe respiratory system diseasesthe digestive system diseasesthe circulatory system diseasesthe urinary system diseasesthe endocrine system diseasesthe blood system diseasesskin disordersgynecological diseasesophthalmic diseasesmental disordersinflammatory disordersliver diseasestumor and deficiency diseases in humans; Medicines in capsule form for the treatment of the nervous system diseasesthe immune system diseasesthe cardio-vascular system diseasesthe metabolic system diseasesthe respiratory system diseasesthe digestive system diseasesthe circulatory system diseasesthe urinary system diseasesthe endocrine system diseasesthe blood system diseasesskin disordersgynecological diseasesophthalmic diseasesmental disordersinflammatory disordersliver diseasestumor and deficiency diseases

Publicações

Histórico de despachos e eventos da marca no USPTO.

38 publicações encontradas

INNT

TOTAL INVALIDATION PROCESSED BY THE IB

24/10/2022

INTS

TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB

26/09/2022

INPC

INVALIDATION PROCESSED

26/09/2022

INTR

TOTAL INVALIDATION OF REG EXT PROTECTION CREATED

31/08/2022

C71T

CANCELLED SECTION 71

31/12/2021

RNWL

INTERNATIONAL REGISTRATION RENEWED

14/05/2020

NREP

NEW REPRESENTATIVE AT IB RECEIVED

17/04/2020

NA71

NOTICE OF ACCEPTANCE OF SEC. 71 - MAILED

07/04/2017

71AG

REGISTERED-SEC.71 ACCEPTED

06/04/2017

EROP

TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED

21/03/2017

PR71

POST REGISTRATION ACTION MAILED - SEC.71

09/03/2017

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

06/03/2017

ES71

TEAS SECTION 71 RECEIVED

20/09/2016

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

20/09/2016

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

26/02/2013

FICS

FINAL DISPOSITION NOTICE SENT TO IB

27/09/2011

FIMP

FINAL DISPOSITION PROCESSED

27/09/2011

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

14/09/2011

R.PR

REGISTERED-PRINCIPAL REGISTER

14/06/2011

PUBO

PUBLISHED FOR OPPOSITION

29/03/2011

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

10/03/2011

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

10/03/2011

NPUB

NOTICE OF PUBLICATION

09/03/2011

LAW OFFICE PUBLICATION REVIEW COMPLETED

24/02/2011

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

17/02/2011

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

15/02/2011

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

15/02/2011

ALIE

ASSIGNED TO LIE

07/02/2011

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

31/01/2011

RFNT

REFUSAL PROCESSED BY IB

19/09/2010

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

24/08/2010

MAFR

APPLICATION FILING RECEIPT MAILED

24/08/2010

RFRR

REFUSAL PROCESSED BY MPU

23/08/2010

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW